Alkem Labs completes acquisition of 100% stake in Adroit Biomed

Alkem Labs has completed the acquisition of a 100 percent stake in M/s. Adroit Biomed Limited in accordance with the conditions prescribed in the share purchase agreement dated 28th March, 2025.

Following the transaction, Adroit will now be a wholly owned subsidiary of the Company.

The acquisition is valued at Rs 140 crores, payable in two tranches, subject to adjustment on account of debt & debt like items & change in normalized working capital as on closing date and other appropriate closing adjustments, the company had earlier informed in its February BSE filing.

Read also: SBI Mutual Fund acquires additional shares of Alkem Labs for Rs 300 crore

Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, Ophthalmology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Read also: Alkem Labs appoints Shirish Purushotham Ambulgekar at senior management position